Immunotherapy turned brain cancers from ‘cold’ to ‘hot’ in mouse study, as clinical trials advance

LONDON — The promise of immunotherapies to treat cancer has yet to reach brain tumors.

It’s difficult to deliver medicines into the brain for a host of reasons. In particular, brain tumors are able to suppress the body’s immune activity and have comparably few genetic vulnerabilities that cancer drugs can target. They’re considered immunologically “cold.”

That hasn’t stopped researchers from trying various ways to enlist the body’s own immune system to stamp out brain tumors. Past studies have shown that treatments like checkpoint inhibitors and personalized cancer vaccines can rally some immune response against these cancers. Such findings have inspired hope that there may be potential for immunotherapies in neuro-oncology after all.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $399/year

$30 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Log In